Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Total Debt (2021 - 2024)

Roivant Sciences (ROIV) has disclosed Total Debt for 4 consecutive years, with $49.8 million as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Total Debt fell 75.92% year-over-year to $49.8 million, compared with a TTM value of $49.8 million through Jun 2024, down 75.92%, and an annual FY2024 reading of $200.7 million, up 165.7% over the prior year.
  • Total Debt was $49.8 million for Q2 2024 at Roivant Sciences, down from $200.7 million in the prior quarter.
  • Across five years, Total Debt topped out at $217.7 million in Q4 2023 and bottomed at $32.6 million in Q1 2022.
  • Average Total Debt over 4 years is $155.4 million, with a median of $192.3 million recorded in 2022.
  • The sharpest move saw Total Debt crashed 82.13% in 2022, then surged 521.22% in 2023.
  • Year by year, Total Debt stood at $204.0 million in 2021, then fell by 4.39% to $195.1 million in 2022, then grew by 11.59% to $217.7 million in 2023, then plummeted by 77.12% to $49.8 million in 2024.
  • Business Quant data shows Total Debt for ROIV at $49.8 million in Q2 2024, $200.7 million in Q1 2024, and $217.7 million in Q4 2023.